MEC (Medical Excellence Capital) is a company that combines investment professionals and operators with a proprietary national medical network platform to create a venture firm in life sciences. It deploys precision capital to nurture and advance precision health innovations that solve complex medical problems.

MEC is an early-stage life science venture fund that combines accomplished investment professionals and operators with a proprietary national medical network platform to create the most unique venture firm in life sciences. MEC deploys precision capital to nurture and advance the precision health innovations that solve the biggest, most complex medical problems.

Medical Excellence Capital, LLC

Congratulations to Medical Excellence Capital's portfolio company Aspen Neuroscience, Inc.!

We are thrilled to announce that Aspen Neuroscience, Inc. has received an $8 Million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM). This grant will support the first U.S. multi-center, multi-patient Phase 1/2a trial of an investigational stem cell-derived dopaminergic neuron replacement therapy, ANPD001, for patients with Parkinson's disease. This milestone brings us one step closer to revolutionizing the treatment landscape for neurodegenerative disorders. Medical Excellence Capital is proud to support the incredible, transformative work being done by everyone at Aspen!

Read more below: 

#ParkinsonsDisease #Neurodegeneration #CellTherapy #Biotechnology #VentureCapital #CellandGeneTherapy #regenerativemedicine

Exciting to see Olga Troyanskaya was the keynote speaker at a Cold Spring Harbor Laboratory symposium this past Friday, where attendees, including our MEC founder John Prufeta were thoroughly impressed! Olga's captivating insights into #AI and #precisionmedicine showcased her unparalleled expertise in the field. Her talk on the work being conducted in her lab, along with her vision for the future was incredibly well-received by an august audience of fellow scientists. Olga serves on MEC’s SAB, currently leading Precision Medicine and the Lewis Sigler Institute of Integrative Genomics at Princeton University. John and so many others enjoyed the opportunity to be part of such an enlightening experience! MEC is proud that our charitable giving program, The Medical Excellence Foundation, recently awarded The Troyanskaya Lab a gift to further Olga's research. #KeynoteSpeaker #ScienceLeadership #ColdSpringHarbor #MECExpert

🌟 Exciting News in Neuroscience Innovation! 🌟

Medical Excellence Capital portfolio company Aspen Neuroscience, Inc. recently announced a significant milestone in Parkinson’s disease treatment. The first patient has been dosed in their groundbreaking Phase 1/2a clinical trial for autologous neuronal cell replacement therapy.

This innovative therapy involves using the patient's own cells to create dopamine-producing neurons, which are then transplanted back into the patient. The goal is to potentially halt or reverse the neurodegenerative effects of Parkinson's, offering hope to millions suffering worldwide.

We're thrilled to witness this leap towards a potential new treatment for Parkinson’s disease and applaud the entire time for their tireless work. This is not just a step forward for Aspen Neuroscience, Inc. but a giant leap for medical science and those affected by this debilitating condition.

🔗 Read more about this pioneering trial here: 

#ParkinsonsDisease #HealthcareInnovation #MedicalScience #neurology #biotechnology #celltherapy‍‍‍‍‍‍‍

Metric
Company Name	MEC
Symbol
MSH ID	COM:MEDEXCELCAP
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital in Life Sciences
Country	US
Stage
Employee Count	13
Website	medexcelcap.com
LinkedIn	medexcelcap
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MEDEXCELCAP

MEC

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue